

22 November 2023

Extension of Cleansing Offer Closing Date

Melodiol Global Health Limited (ASX:ME1) ('Melodiol' or 'the Company') refers to the prospectus dated 31 October 2023 and supplementary prospectus dated 6 November 2023 (together, 'Prospectus'). The Company wishes to advise that the Closing Date for the Cleansing Offer under the Prospectus has been extended from Wednesday, 22 November 2023 (as extended in the ASX announcement dated 13 November 2023) to Friday, 1 December 2023.

The Company reserves the right to amend the Closing Date of the Cleansing Offer subject to the Corporations Act, the ASX Listing Rules and other applicable laws. Further details with respect to the Cleansing Offer are set out in the Prospectus.

Authority and Contact Details

This announcement has been authorised for release by the Managing Director of Melodiol Global Health Limited, William Lay.

For further information, please contact:

Investor Enquiries

Melodiol Global Health Limited

E: info@cresopharma.com

P: +61 (0) 497 571 532

About Melodiol

Melodiol Global Health Limited (ASX:ME1) brings the best of cannabis and other plant-based products to better the lives of people and animals. Melodiol strives for the highest quality in its products. It develops cannabis, hemp-derived and other plant based therapeutic, nutraceutical, and lifestyle products with wide consumer reach. To learn more please visit: <https://melodiolglobalhealth.com/>.

Melodiol offices:

Australia: Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

Canada: 59 Payzant Drive, Windsor, Nova Scotia, B0N 2T0 and 50 Ivey Ln, Windsor, Nova Scotia, B0N 2T0

Forward Looking statements

This announcement contains forward-looking statements with respect to Melodiol and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Melodiol could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Melodiol and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Melodiol has no obligation to up-date such statements, except to the extent required by applicable laws.